In a pioneering trial taking place in London, doctors are harnessing patients’ own immune systems in an effort to find a new effective treatment for resistant head and neck cancer. The trial of the novel therapy, which involves genetically engineering the patient’s white blood cells so that they recognise and attack the tumour, is taking place at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ and King’s College London, with funding from the Wellcome Trust and the J P Moulton Charitable Foundation.
